Crossmark

Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report

Crossref DOI link: https://doi.org/10.1186/s13256-022-03552-y

Published Online: 2022-08-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Taenaka, Ryutaro https://orcid.org/0000-0002-2378-6531
Shimokawa, Sakurako

Katayama, Ayako

Nagao, Toshihiko

Obara, Teppei

Nishimura, Naoaki

Tsujimoto, Atsushi

Kohno, Kentaro

Aoki, Kenichi

Ogawa, Ryosuke
License Information

Text and Data Mining valid from 2022-08-18

Version of Record valid from 2022-08-18
More Information

Article History

Received: 1 June 2022

Accepted: 29 July 2022

First Online: 18 August 2022

Declarations

:

: This study protocol was reviewed and approved by the review board at JCHO Kyushu Hospital, approval number 768. The patient provided written informed consent to participate in this study.

: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

: The authors have no conflicts of interest to declare.

Document is current

Any future updates will be listed below